



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

April 12, 2022

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code: 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Subject

- **Assignment of Trademark for Azmarda® indicated for heart failure patients with reduced ejection fraction (HfrEF) from Novartis AG, Switzerland for India**

Reference

- **Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

We refer to our letter dated April 1, 2022 intimating you about the approval by the Board of directors of the Company at its meeting held on April 1, 2022, for acquisition of the brand 'Azmarda' from Novartis AG, Switzerland. In compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we further wish to inform you that the aforesaid transaction of acquisition of the brand 'Azmarda' from Novartis AG, Switzerland has been successfully completed yesterday.

You are requested to take the same on record.

Thanking you,

Yours sincerely

For J. B. Chemicals & Pharmaceuticals Ltd.

Sandeep Phadnis
Vice President – Secretarial
& Company Secretary

📍 **Registered Office:**
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

📍 **Corporate Office:**
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500
☎ +91 22 2431 5331 / 2431 5334
✉ info@jbcpl.com
🌐 www.jbcpl.com
CIN: L24390MH1976PLC019380